glp-1 vs sglt2 diabetes Cardiorenal Protection: Potential of Inhibitors and Receptor Agonists in the Treatment of Type 2 | Diabetes Therapy Renal outcomes of SGLT2 inhibitors

The most commonly reported side effects are increased appetite (consistent with ghrelin receptor activation), mild water retention and transient edema in the first 1-2 weeks, and occasional muscle cramping

tirzepatide naturally suppresses appetite within hours

For that reason, any decision to pause or stop GLP-1 therapy should always be made in consultation with a qualified healthcare provider who can document the plan, adjust dosing, and help protect continued coverage

IKK phosphorylates targets in the NF-B signaling pathway, thereby activating the NF-B pathway

to regulate microbial composition (Reverter et al., 2018)